NCT05358808
ACHIEVE - Efficacy and Effectiveness of Adoptive Cellular tHerapy wIth Ex-Vivo Expanded Allogeneic γδ T-lymphocytes (TCB008) for Patients With Refractory or Relapsed Acute Myeloid Leukaemia (AML)
Phase: Phase 2
Role: Lead Sponsor
Start: Aug 15, 2022
Completion: Jul 30, 2025